Revolution Medicines (RVMD) Current Deferred Revenue (2019 - 2023)

Revolution Medicines has reported Current Deferred Revenue for 5 years, with the latest figure at $1.4 million in Q1 2023.

• For the quarter ending Q1 2023, Current Deferred Revenue fell 87.46% year-over-year to $1.4 million; the trailing twelve-month figure through Mar 2023 stood at $1.4 million (down 87.46% YoY), and the FY2022 full-year result was $4.5 million, down 63.92% from the prior year.
• Current Deferred Revenue for Q1 2023 stood at $1.4 million, down from $4.5 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $16.4 million in Q1 2020, with the low at $609000.0 in Q4 2019.
• Average Current Deferred Revenue over 5 years is $9.8 million, with a median of $10.7 million recorded in 2021.
• Year-over-year, Current Deferred Revenue jumped 1888.67% in 2020 and tumbled 87.46% in 2023.
• Tracing RVMD's Current Deferred Revenue over 5 years: stood at $609000.0 in 2019, then jumped by 1888.67% to $12.1 million in 2020, then increased by 2.04% to $12.4 million in 2021, then slumped by 63.92% to $4.5 million in 2022, then plunged by 67.84% to $1.4 million in 2023.
• The last three Current Deferred Revenue figures came in at $1.4 million (Q1 2023), $4.5 million (Q4 2022), and $9.7 million (Q3 2022), per Business Quant data.

Peer Comparison